PD0332991 in Patients With Advanced or Metastatic Liposarcoma
The purpose of this study is to find out what effects, good and/or bad, PD0332991 has on the patient and on the liposarcoma.
PD0332991 is an investigational drug. An investigational drug is a medication that has not been approved for marketing by the Food and Drug Administration (FDA). PD0332991 blocks a protein called CDK4 which is part of a pathway in liposarcoma cells that is over-active. The investigators hope that blocking CDK4 will shut down this pathway in the liposarcoma cells and stop tumors from growing. PD0332991 is an oral medication.
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Phase II Study Of PD0332991 in Patients With Advanced or Metastatic Liposarcoma|
- to determine the proportion of patients with advanced/metastatic liposarcoma who are progression-free at 12 weeks [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]PFS, defined as RECIST 1.1 CR + PR + SD) when treated with PD0332991
- Overall response rate (defined as CR + PR) [ Time Frame: 2 years ] [ Designated as safety issue: No ]
- Overall survival [ Time Frame: 2 years ] [ Designated as safety issue: No ]
- Clinical benefit rate (CR + PR + SD) [ Time Frame: 2 years ] [ Designated as safety issue: No ]
|Study Start Date:||September 2010|
|Estimated Study Completion Date:||September 2015|
|Estimated Primary Completion Date:||September 2015 (Final data collection date for primary outcome measure)|
This is a phase II study of PD0332991 in patients with advanced / metastatic liposarcoma. A one-stage design is used to determine whether patients treated with PD0332991 achieved a PFS rate of ≥ 40% at 12 weeks.
Treatment will consist of either:
Schedule 2/1: PD0332991 200mg given once daily by mouth for 14 consecutive days, followed by 7 days of rest. A cycle will be defined as 21 days.
Schedule 3/1: PD0332991 125mg given once daily by mouth for 21 consecutive days, followed by 7 days of rest. A cycle will be defined as 28 days. Following the positive results of the study, a new Expansion Cohort has been added to permit enrollment of up to 20 additional patients.
Expansion Cohort: Dosed as per Schedule 3/1
Please refer to this study by its ClinicalTrials.gov identifier: NCT01209598
|United States, New York|
|Memorial Sloan Kettering Cancer Center|
|New York, New York, United States, 10065|
|Principal Investigator:||Mark Dickson, MD||Memorial Sloan Kettering Cancer Center.|